Axolotl Biologix and Carmell Therapeutics enter merger deal

As per the deal terms, shareholders of Axolotl will receive an initial equity price of $65m.

September 13, 2023

With the deal closing, Axolotl will now function as a completely owned Carmell subsidiary. Credit: metamorworks/Shutterstock.com.

Moonshot incubator client Axolotl Biologix has finalised a merger with Carmell Therapeutics to bolster the regenerative medicine sector.

The merger will combine the expertise of Axolotl Biologix in regenerative therapies with Carmell’s capabilities in utilising the innate healing properties of the body.

Axolotl Biologix focuses on progressing regenerative medicines to design and develop human amnion-based allograft products for soft tissue repair, as well as aesthetic and orthopaedic applications.

As per the deal terms, shareholders of Axolotl will receive an initial equity price of $65m, comprising $8m in cash and $57m in Carmell stock on the closing of the transaction.

Axolotl shareholders are also entitled to receive milestone equity payments of up to $75m in the future.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the deal closing, Axolotl will now function as a completely owned Carmell subsidiary.

Moonshot president and CEO Scott Hathcock said: “The merger between Carmell Therapeutics and Axolotl Biologix exemplifies the type of innovation and growth that Moonshot is designed to cultivate.

“This merger with an industry giant like Carmell Therapeutics is a significant development for the future of regenerative medicine.”

The combined business will also possess the scientific proficiency of Carmell and Axolotl’s practical developments.

A regenerative medicine platform company, Carmell develops allogeneic plasma-based biomaterials to enhance innate regenerative pathways for various bone and soft tissue indications.